biomea fusion
Yongli Su is a scientist with extensive experience in the biotechnology and pharmaceutical industries, currently employed at Biomea Fusion since September 2021. Previous roles include positions at Bristol Myers Squibb, MyoKardia, and Arcus Biosciences, where contributions as a scientist and associate scientist were made. Yongli Su also worked as a contractor at Gilead Sciences and held various roles at Amgen, including associate scientist and senior associate, from May 2005 to December 2014. Yongli Su holds a Master's degree in Organic Chemistry from the Shanghai Institute of Organic Chemistry in P.R. China.
biomea fusion
Biomea Fusion, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of irreversible small molecules to treat patients with genetically defined cancers. The company was formed in 2017 by a small group of biotech executives that came together with the common goal of achieving better therapies for patients.